The application of Tau protein testing to gastric cancer patients treated with paclitaxel

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Chinese Science Bulletin

• Publication date

  2013-11-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/S11434-013-6078-6
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.

  2010cited by this paper
• Microtubules and resistance to tubulin-binding agents

  2010cited by this paper
• Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial.

  2009cited by this paper
• Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial

  2009cited by this paper
• Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group

  2008cited by this paper
• Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?

  2008cited by this paper
• Chemotherapy for advanced gastric cancer: across the years for a standard of care

  2007cited by this paper
• Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor–Positive Breast Cancer

  2007cited by this paper
• Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment

  2006cited by this paper
• Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil

  2006cited by this paper
• Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

  2006cited by this paper
• Microtubule Associated Protein (MAP)-Tau: A Novel Mediator of Paclitaxel Sensitivity In Vitro and In Vivo

  2005cited by this paper
• Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.

  2005cited by this paper
• Evidence for two distinct binding sites for tau on microtubules.

  2004cited by this paper
• Messengers of cell death: apoptotic signaling in health and disease.

  2003cited by this paper
• Expression of microtubule-associated protein tau by gastrointestinal stromal tumors.

  2001cited by this paper
• Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.

  1999cited by this paper

• No citing papers are available for this paper.